Gene - I posted on Friday that if the buy opportunity afforded by somebody dumping calls made things worse, that I'd swallow hard and buy. Did just that, getting Feb. 50 and May 50 calls. Held but didn't add to my Nov. 47.5s, which are about At The Money - no real advantage in adding there. I continue to hold my AGPH, and the fear mongering that flushed money out the door and gave a little room for some shorts to cover (if they're smart) looks like a delightful buy opportunity.
As to the substance of the report from thestreet.com, I haven't read it, but based on margie's report of it, and the article itself, there are no definitive conclusions to be drawn, and very little solid info on which to base a medical (or investment) decision. With earnings coming up soon and European approval sometime soon as well, I think the stampede will be back in, instead of out. Montgomery's putative downgrade is annoying, since it lends unwarranted credibility to the reports most fearful if unsubstantiable inference - that Vira is somehow not as good as the other PIs. It will be up to Agouron to manage this situation; if they don't, they need to be spanked - the late entry poster needs to be countervened with solid data from their trials that support the cross resistivity concept discussed here and elsewhere.
So, buy and hold for me.
Regards,
Randy |
